Lincoln Pharmaceuticals
LINCOLN · NSEValuation
Blended fair value using DCF and peer comparison methods.
Peer comparison
How this company stacks up against sector peers on valuation and quality metrics.
Pharmaceuticals · 7 peers · sector medians shown
| Company | Mkt Cap | P/E | P/B | EV/EBITDA | ROE | Net Margin | Rev CAGR 3y |
|---|---|---|---|---|---|---|---|
Lincoln Pharmaceuticals LINCOLN · you | ₹1,229 Cr | 13.9× | 1.6× | 12.6× | 11.6% | 13.1% | 9.6% |
| Sector median | — | 32.7× | 4.2× | 22.6× | 12.9% | 24.7% | 14.2% |
| Caplin Point Laboratories CAPLIPOINT | ₹17,160 Cr | 25.1× | 4.5× | 22.6× | 17.9% | 29.3% | 14.2% |
| Cohance Lifesciences COHANCE | ₹16,515 Cr | 92.3× | 4.2× | 41.7× | 4.6% | 7.9% | 19.2% |
| NATCO Pharma NATCOPHARM | ₹15,503 Cr | 11.0× | 1.7× | 10.9× | 15.4% | 34.8% | 14.6% |
| Jubilant Pharmova JUBLPHARMA | ₹15,442 Cr | 38.2× | 2.1× | 15.3× | 5.6% | 4.8% | 9.6% |
| Concord Biotech CONCORDBIO | ₹13,302 Cr | 51.3× | 6.6× | 36.5× | 12.9% | 24.7% | 7.3% |
| Blue Jet Healthcare BLUEJET | ₹8,168 Cr | 32.7× | 6.0× | 27.8× | 18.2% | 26.2% | 9.5% |
| Kilitch Drugs (India) Limited KILITCH | ₹599 Cr | 19.9× | 2.1× | 18.8× | 10.8% | 12.8% | 19.0% |
Lincoln trades at a discount to sector peers on P/E (13.9× vs median 32.7×). This may signal undervaluation — or reflect lower expected growth or higher perceived risk versus the peer group.
Business quality
Key profitability, efficiency, and solvency metrics.
Financial health
Piotroski F-Score, Altman Z-Score, and key solvency ratios.
Full financial data
Charts and annual statements for income, balance sheet and cash flow.
Income trend
Revenue, profit and margin trends over time.
Cash flow
Where cash comes from and where it goes.
Balance sheet
Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.
How the company is funded — equity is owners' money, debt is long-term borrowing, current liabilities are short-term obligations.